[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"hypertension-in-pregnancy\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:hypertension-in-pregnancy":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,12,0,[8,54,81,106,132,158,190,218,247,280,303,325],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":31,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":42,"lastUpdatePostDateStruct":43,"startDateStruct":46,"completionDateStruct":48,"leadSponsor":50,"locationsCount":53},"100580335","momshome-a-storytelling-based-mobile-health-intervention-to-improve-blood-pressure-management-in-pregnancy-100580335",false,"NCT06835959","Moms@Home: A Storytelling-based Mobile Health Intervention to Improve Blood Pressure Management in Pregnancy","Development of a Mobile Health Intervention to Improve Blood Pressure Management in Pregnancy (Moms@Home)","Moms@Home","Inclusion Criteria:\n\n* Age 18-50\n* English or Spanish speaking\n* A diagnosis of gestational (20-26 weeks gestational age) or chronic hypertension (8-26 weeks gestational age)\n* Singleton or multiple gestation pregnancy,\n* A patient of the University of Massachusetts Memorial Health Obstetrics\u002FMaternal and Fetal Medicine clinics in Worcester, Massachusetts\n* Willing to share home blood pressure monitoring data\n* Comfortable with the use of smartphones and mobile apps\n\nExclusion Criteria:\n\n* Severe hypertension (Systolic blood pressure ≥160 mmHg or Diastolic blood pressure ≥100 mmHg)\n* Current diagnosis of preeclampsia\n* Active substance use\n* Serious physical illness (e.g., unable to interact with a smart device)\n* Enrolled in another home blood pressure monitoring program\n* Excluded from study participation by their provider\n* Inability to provide informed consent\n* Prisoners\u002Finstitutionalized individuals","FEMALE","18 Years","50 Years",{"count":21,"type":22},100,"ESTIMATED","INTERVENTIONAL",[25],"NA","This pilot study will examine the effects of a digital health approach, Moms@Home, on home blood pressure monitoring in a diverse population of pregnant women with hypertension.",[28,29,30],"Hypertension in Pregnancy","Chronic Hypertension","Gestational Hypertension",[32,15,33,34,35,36,37,38,39,40],"Hypertension in pregnancy","Mobile health intervention","Blood pressure","Blood pressure management","Hypertension","Gestational hypertension","Storytelling","Home blood pressure monitoring","Storytelling mobile intervention","RECRUITING","2026-06-12",{"date":44,"type":45},"2026-06-16","ACTUAL",{"date":47,"type":45},"2025-05-16",{"date":49,"type":22},"2027-11-16",{"name":51,"class":52},"University of Massachusetts, Worcester","OTHER",1,{"id":55,"slug":56,"hasResults":11,"nctId":57,"briefTitle":58,"officialTitle":59,"acronym":4,"eligibilityCriteria":60,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":61,"targetDuration":4,"studyType":23,"phases":63,"briefSummary":64,"conditions":65,"keywords":67,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":53},"100551905","conical-forearm-and-cylindrical-upper-arm-non-invasive-blood-pressure-nibp-measurements-in-pregnant-patients-100551905","NCT06466161","Conical Forearm and Cylindrical Upper Arm Non-Invasive Blood Pressure (NIBP) Measurements in Pregnant Patients","Evaluation of the Agreement Between Conical Forearm and Cylindrical Upper Arm Non-Invasive Blood Pressure (NIBP) Measurements in Pregnant Patients","Inclusion Criteria:\n\n* Women who are 18 years of age or older with a\n* Body mass index (BMI) of 20 kg\u002Fm2 or greater\n* Present to Labor and Delivery with or without a diagnosis of gestational hypertension, preeclampsia, or chronic hypertension with super-imposed preeclampsia, in spontaneous labor or for induction of labor\n\nExclusion Criteria:\n\n* Significant peripheral arterial disease resulting in at least a 10 mm Hg blood pressure difference between both arms\n* History of repaired or unrepaired congenital heart disease\n* History of significant arrythmia\n* History of pacemaker or implantable cardioverter defibrillator placement\n* History of sickle cell disease\n* History of Raynaud's phenomenon on any extremity\n* History of lymph node dissection of either upper extremity\n* Patients who are less than 18 years of age",{"count":62,"type":22},110,[25],"The diagnosis of hypertensive disease during pregnancy is predicated on strict blood pressure thresholds: 140\u002F90 on at least two occasions measured four hours apart for both gestational hypertension and preeclampsia. An improvement in diagnostic accuracy of even 5mm Hg would be significant, as reflected by the US Association for the Advancement of Medical Instrumentation (AAMI), the British Hypertension Society, the European Society of Hypertension (ESH) Working Group on Blood Pressure (BP) Monitoring, and the International Organization for Standardization (ISO)consensus for validation of non-invasive blood pressure (NIBP) devices during pregnancy. Given the known inaccuracies of upper arm cylindrical cuff measurements in morbidly obese patients, a conical cuff which provides more accurate measurements will translate into direct patient benefit via more informed diagnosis and management. Fewer women may be exposed to unnecessary treatment, preterm delivery, and\u002For cesarean section. Recognizing the increasing prevalence of morbid obesity and hypertensive disease amongst pregnant women in the United States, the identification of a more accurate non-invasive cuff is desperately needed. Increasing the accuracy of NIBP measurements on Labor and Delivery has the potential to directly impact the management of tens of thousands of morbidly obese pregnant women diagnosed with hypertensive disease in the United States every year. Establishing the level of agreement between conical forearm and cylindrical upper arm cuffs will shed light on the presence and magnitude of any disparity between measurement methods.\n\nSTUDY ENDPOINTS:\n\nPrimary Outcome Measures:\n\n* Agreement between conical and cylindrical cuff systolic blood pressure across groups\n* Agreement between conical and cylindrical cuff diastolic blood pressure across groups\n\nSecondary Outcome Measures:\n\n• Agreement between conical and cylindrical cuff mean arterial pressure",[28,36,66],"Obesity",[36,68,69,70,66,71],"Conical Blood Pressure Cuff","Cylindrical Blood Pressure Cuff","Pregnancy","Non invasive blood pressure","2026-05-21",{"date":74,"type":45},"2026-05-26",{"date":76,"type":45},"2025-04-29",{"date":78,"type":22},"2027-09-01",{"name":80,"class":52},"Northwestern University",{"id":82,"slug":83,"hasResults":11,"nctId":84,"briefTitle":85,"officialTitle":86,"acronym":4,"eligibilityCriteria":87,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":88,"enrollmentInfo":89,"targetDuration":4,"studyType":23,"phases":91,"briefSummary":92,"conditions":93,"keywords":94,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":99,"startDateStruct":101,"completionDateStruct":102,"leadSponsor":104,"locationsCount":53},"100620353","telehealth-and-remote-blood-pressure-100620353","NCT07356518","Telehealth and Remote Blood Pressure","Feasibility and Safety of Incorporating Telehealth Visits Combined With Remote Blood Pressure Monitoring in the Management of Chronic Hypertension in Pregnancy","Inclusion Criteria:\n\n* prior diagnosis of Chronic hypertension (cHTN)\n* Pregnant women\n* Known: documented diagnosis or on antihypertensive medication prior to pregnancy\n\nExclusion Criteria:\n\n* Any significant chronic medical or psychiatric illness that, in the investigator's opinion, would prevent participation in the study\n* Cardiac disorders: cardiomyopathy, angina, Coronary Artery Disease (CAD)\n* Current substance abuse disorder\n* Multifetal pregnancy\n* Participation in another study without prior approval\n* Plan to deliver outside Atrium Health Wake Forest Baptist\n* Prior stroke\n* Severe hypertension\n* Suspected or known fetal major structural\u002Fchromosomal abnormality or fetal demise","45 Years",{"count":90,"type":22},60,[25],"The purpose of this research study is to compare the management of chronic hypertension during pregnancy using telehealth visits with blood pressure telemonitoring and health coaching as compared to standard in person clinic visits. The study involves pregnant woman aged 18-45 who are receiving care for chronic hypertension. Participation in this research study will last until their baby is delivered. The number of in-person clinic visits depends on the participant's treatment assignment. Those assigned to telehealth visits will have telehealth visits alternating with clinic visits every two weeks until the end of pregnancy week 31. Those assigned to telehealth visits will also have five sessions with a health coach via telephone or video from the time of enrollment until the end of pregnancy week 36.",[36,28],[95,96,97],"high blood pressure","pre-eclampsia","hypertension during pregnancy","2026-04-22",{"date":100,"type":45},"2026-04-27",{"date":98,"type":45},{"date":103,"type":22},"2026-12",{"name":105,"class":52},"Wake Forest University Health Sciences",{"id":107,"slug":108,"hasResults":11,"nctId":109,"briefTitle":110,"officialTitle":111,"acronym":112,"eligibilityCriteria":113,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":114,"targetDuration":4,"studyType":23,"phases":116,"briefSummary":117,"conditions":118,"keywords":119,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":123,"lastUpdatePostDateStruct":124,"startDateStruct":126,"completionDateStruct":128,"leadSponsor":130,"locationsCount":53},"100524211","inorganic-nitrate-supplementation-in-chronic-hypertensive-pregnancies-100524211","NCT06105775","Inorganic Nitrate Supplementation in Chronic Hypertensive Pregnancies","Inorganic Nitrate Supplementation for Blood Pressure Control in Chronic Hypertensive Pregnancies From the 2nd Trimester (NIT_CH): a Triple-Blind Randomized Placebo-Controlled Trial","NIT_CH","Inclusion Criteria:\n\n* Pregnant women diagnosed with chronic hypertension (systolic blood pressure above 140 mmHg and\u002For diastolic blood pressure above 90 mmHg before pregnancy or before 20 weeks of gestation) as defined by the Brazilian Network for Studies on Hypertension in Pregnancy (RBEHG, Brazilian acronym) Protocol and Chronic Hypertension\u002FPreeclampsia by the Brazilian Federation of Gynecology and Obstetrics Associations (FEBRASGO, Brazilian acronym) Protocol.\n* Patients on monotherapy with methyldopa as treatment at the time of inclusion.\n* Women with less than 16 weeks of gestation confirmed by first-trimester ultrasonography confirming gestational age.\n\nExclusion Criteria:\n\n* Multiple pregnancies, age below 18 years old, inability to provide informed consent, or history of low adherence to medication therapy.\n* Patients with uncontrolled chronic hypertension, with blood pressure values above 160x110mmHg.\n* History of food allergies, especially hypersensitivity to beetroot.\n* Users of illicit drugs, smokers, or alcohol abusers.\n* Diagnosis of coronary artery disease, congestive heart failure (moderate to severe), moderate to severe liver failure, chronic renal insufficiency (with plasma creatinine clearance less than 30 ml\u002Fmin\u002F1.73 m² of body surface), pre-existing type 1 diabetes, and type 2 diabetes.\n* Pregnant women who frequently used non-steroidal anti-inflammatory drugs, nasal decongestants, and anorectics before getting pregnant; users of proton pump inhibitors and H2 receptor antagonists or any other medication that interferes with stomach pH, starting 2 weeks before the beginning and continuing throughout the remainder of the study.",{"count":115,"type":22},144,[25],"High blood pressure during pregnancy poses significant risks to both the mother and baby. A combination of factors, including advancing maternal age, rising obesity rates, and metabolic health issues, have amplified the prevalence of this condition. While conventional medicines are available, safety during pregnancy remains a concern. Recent studies suggest that inorganic nitrate might be a safer alternative. The power of nitrate lies in its ability to stimulate the body's production of a compound that aids in dilating and relaxing blood vessels. Preliminary studies conducted on mice and a select group of pregnant women have yielded encouraging results. Early tests indicated that after consuming inorganic nitrate, there was a reduction in blood pressure and an improvement in the health of the mother's uterine artery-a vital vessel responsible for nourishing the fetus. Our study aims to investigate the effects of inorganic nitrate supplementation on pregnant women from the start of their pregnancy and continuing it throughout their term. If our findings are positive, it could revolutionize how we approach blood pressure management during pregnancy, paving the way for healthier futures for both mothers and babies.",[28,36,70],[120,28,121,122],"Endothelial Dysfunction","Nitric Oxide","inorganic nitrate","2026-04-15",{"date":125,"type":45},"2026-04-20",{"date":127,"type":45},"2025-03-06",{"date":129,"type":22},"2027-07",{"name":131,"class":52},"University of Sao Paulo",{"id":133,"slug":134,"hasResults":11,"nctId":135,"briefTitle":136,"officialTitle":137,"acronym":138,"eligibilityCriteria":139,"healthyVolunteers":140,"sex":17,"minAge":141,"maxAge":142,"enrollmentInfo":143,"targetDuration":4,"studyType":23,"phases":145,"briefSummary":147,"conditions":148,"keywords":4,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":149,"lastUpdatePostDateStruct":150,"startDateStruct":152,"completionDateStruct":154,"leadSponsor":156,"locationsCount":53},"100515290","phase-1-chronic-hypertension-and-pregnancy-2-chap2-pilot-project-100515290","NCT05989581","Chronic Hypertension and Pregnancy 2 (CHAP2) Pilot Project","Treatment of American Heart Association\u002FAmerican College of Cardiology Stage 1 Hypertension in Pregnancy: A Randomized Control Trial","CHAP2","Inclusion Criteria:\n\n* Viable singleton gestation\n* No fetal anomalies\n* Blood pressures 130-139\u002F80-89mmHg on two occasions at least 4 hours apart prior to 20 weeks gestation\n* Planning to deliver at UAB Hospital\n* No indication for pregnancy termination\n* Receiving care at the UAB prenatal clinics\n\nExclusion Criteria:\n\n* Declines Randomization\n* Known diagnosis of chronic hypertension ( BP ≥ 140\u002F90mmHg) or current antihypertensive medication use\n* Fetal demise diagnosed prior to enrollment\n* Known major structural of chromosomal abnormalities prior to enrollment\n* Contraindication to first line antihypertensive (Nifedipine\u002F Labetalol)\n* Comorbidities requiring BP goals \\\u003C 130\u002F80mmHg",true,"14 Years","89 Years",{"count":144,"type":22},74,[146],"PHASE1","The CHAP2 study is designed to provide preliminary data for a larger multicenter study to assess whether treatment of stage 1 hypertension (HTN) in pregnancy improves maternal and or neonatal outcomes. The primary objective of this pilot study is to determine if anti-HTN treatment to BP\\\u003C130\u002F80mmHg in pregnant patients with stage 1 HTN is associated with a difference in birthweight percentile at delivery. Patients with stage 1 hypertension in pregnancy will be randomized to BP goals of \\\u003C130\u002F80mmHg or usual care to treatment only if BPs ≥140\u002F90mmHg. For this pilot, the investigator will randomize a total of 74 eligible participants, 37 to active treatment to BP\\\u003C130\u002F80mmHg and 37 to usual care.",[28],"2026-04-03",{"date":151,"type":45},"2026-04-09",{"date":153,"type":45},"2024-04-24",{"date":155,"type":22},"2026-12-31",{"name":157,"class":52},"University of Alabama at Birmingham",{"id":159,"slug":160,"hasResults":11,"nctId":161,"briefTitle":162,"officialTitle":163,"acronym":164,"eligibilityCriteria":165,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":166,"targetDuration":4,"studyType":23,"phases":168,"briefSummary":170,"conditions":171,"keywords":175,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":181,"lastUpdatePostDateStruct":182,"startDateStruct":184,"completionDateStruct":186,"leadSponsor":188,"locationsCount":53},"100576424","phase-4-a-randomized-placebo-controlled-trial-of-dapagliflozin-dapa-for-cardiovascular-risk-reduction-in-the-postpartum-period-of-hypertensive-pregnancies-hp-100576424","NCT06785116","A Randomized, Placebo-controlled Trial of DAPAgliflozin (DAPA) for Cardiovascular Risk Reduction in the Postpartum Period of Hypertensive Pregnancies (HP)","A Randomized, Placebo-controlled Trial of DAPAgliflozin for Cardiovascular Risk Reduction in the Postpartum Period of Hypertensive Pregnancies","DAPA-HP","Inclusion Criteria:\n\n* Admitted for delivery at the University of Michigan (UM) Labor and Delivery (L\\&D) unit or enrolled in the UM postpartum blood pressure monitoring program following a delivery at the UM L\\&D unit\n* Determined to be at least 23 and 0\u002F7 weeks of gestation based on a clinically acceptable dating method (can be a single or multifetal gestation with or without the presence of fetal anomalies) at the time of delivery\n* Consents to participation and must understand\u002Fread\u002Fspeak English with the ability to understand and willingness to sign a written informed consent in English\n* Diagnosed with a hypertensive pregnancy by either of the following criteria:\n\n  * Taking an antihypertensive medication for the diagnosis of chronic or essential hypertension at the time of admission\n  * Hypertension, chronic hypertension, or essential hypertension must be present in the prospective participant's medical record\n  * Antihypertensive\" can be any medication taken for the purpose of blood pressure control per the medical record\n  * A documented hypertensive disorder of pregnancy (gestational hypertension, preeclampsia without severe features, preeclampsia with severe features, superimposed preeclampsia, or eclampsia) prior to delivery\n* Eligible participants must report a planned contraceptive method as part of the consent process, to be noted on their consent document.\n* Has two or more blood pressures ≥160\u002F110 Millimeters of mercury (mmHg) at least 60 minutes apart\n\n  * If an admitted patient does not meet this blood pressure criterion but is otherwise eligible, participants can consent to have a BNP drawn within 12 hours of delivery as an alternative measure of cardiovascular risk (if the brain natriuretic peptide (BNP) is ≥100 Picograms per milliliter (pg\u002Fml), participants are eligible to participate)\n\nExclusion Criteria:\n\n* Non-English speaking\n* Ongoing pregnancy\n* Stated desire to become pregnant within 8 months post-delivery\n* Intention to breastfeed after enrollment\n* BNP ≥1000 pg\u002Fml within 12 hours of delivery, clinical team to be notified of result\n* Comorbidities that may affect cardiovascular risk assessment (per protocol)\n* Contraindication to dapagliflozin (per protocol)",{"count":167,"type":22},200,[169],"PHASE4","This trial is a pilot-scale, single institution randomized, placebo-controlled trial to assess the feasibility, acceptability, and efficacy of administering dapagliflozin for cardiovascular risk reduction in the postpartum period. The target population is patients at high risk of adverse cardiovascular outcomes within five years post-delivery.\n\nEligible participants will be randomized to receive either: 1) dapagliflozin (10mg daily) for six months (DAPA group) or 2) an orally administered, daily placebo (Control group).\n\nThe study hypothesizes:\n\nThe dapagliflozin group will have higher cardiovascular risk reduction scores than the Control Group.",[30,28,172,173,174],"Pre-Eclampsia","Superimposed Pre-Eclampsia","Cardiovascular Complication",[176,177,178,179,180],"Medication","Placebo","Postpartum period","Cardiovascular risk reduction","Echocardiogram","2026-03-01",{"date":183,"type":45},"2026-03-04",{"date":185,"type":45},"2025-03-02",{"date":187,"type":22},"2028-08",{"name":189,"class":52},"University of Michigan",{"id":191,"slug":192,"hasResults":11,"nctId":193,"briefTitle":194,"officialTitle":195,"acronym":196,"eligibilityCriteria":197,"healthyVolunteers":11,"sex":17,"minAge":198,"maxAge":4,"enrollmentInfo":199,"targetDuration":4,"studyType":23,"phases":201,"briefSummary":202,"conditions":203,"keywords":204,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":209,"lastUpdatePostDateStruct":210,"startDateStruct":212,"completionDateStruct":214,"leadSponsor":216,"locationsCount":53},"100594711","phase-4-postpartum-evaluation-of-nifedipine-and-enalapril-for-hypertension-100594711","NCT07023003","Postpartum Evaluation of Nifedipine and Enalapril for Hypertension","Postpartum Evaluation of Antihypertensives for Control of Hypertension: A Randomized Controlled Equivalence Study","PEACE","Inclusion Criteria:\n\n1. admitted for delivery by cesarean or vaginal delivery\n2. 24 weeks gestation or greater\n3. Pregnancy related hypertension(HTN) or chronic hypertension. Pregnancy related hypertension will be defined during the study as either a systolic blood pressure ≥140mmHg or diastolic blood pressure ≥90mmHg on two occasions at least 4 hours apart. This definition is consistent with the ACOG definition for pregnancy related HTN in patients without CHTN.\n\nExclusion Criteria:\n\n1. Absolute contraindication to either nifedipine or enalapril Relative contraindications will be reviewed with PI.\n2. Persistent HR \\\u003C60 or \\>110\n3. Native language other than English","19 Years",{"count":200,"type":22},850,[169],"This is an open label, randomized controlled trial designed to compare nifedipine and enalapril in the management of postpartum hypertension. This is an equivalence study- meaning it is not expected one medication is better than the other. Nifedipine has been shown to be better than another common blood pressure medicine, labetalol, for postpartum hypertension but enalapril which is also used worldwide to manage blood pressure postpartum, has not yet been evaluated or compared to nifedipine.\n\nInvestigators will identify and offer enrollment to women who are admitted for delivery with documented hypertension- participants with either chronic hypertension or pregnancy related hypertension will be included. Our hypothesis is both medications are safe and effective in managing blood pressure and preventing readmission for hypertensive complications during the postpartum period so evaluating the rate of readmission is the primary goal of the study.\n\nThe only intervention of the trial will be to assign which medication the participant starts taking. Any decisions after that point- stopping medication, changing doses, additional medications, discharge from the hospital, etc, will all be at the discretion of the participant's primary provider.",[28],[36,205,206,207,208],"Postpartum","Enalapril","Nifedipine","Readmission","2025-10-20",{"date":211,"type":45},"2025-10-22",{"date":213,"type":45},"2025-07-11",{"date":215,"type":22},"2028-12",{"name":217,"class":52},"Nebraska Methodist Health System",{"id":219,"slug":220,"hasResults":11,"nctId":221,"briefTitle":222,"officialTitle":223,"acronym":224,"eligibilityCriteria":225,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":226,"targetDuration":4,"studyType":23,"phases":228,"briefSummary":229,"conditions":230,"keywords":234,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":239,"lastUpdatePostDateStruct":240,"startDateStruct":242,"completionDateStruct":244,"leadSponsor":245,"locationsCount":53},"100575516","enhancing-intergenerational-health-in-nigeria-peripartum-as-critical-life-stage-for-cardiovascular-health-100575516","NCT06773299","Enhancing Intergenerational Health in Nigeria: Peripartum as Critical Life Stage for Cardiovascular Health","ENhancing Intergenerational HeAlth in Nigeria: Peripartum as Critical Life StagE for CardioVascular Health","ENHANCE-CVH","Inclusion Criteria:\n\n•≥18 years of age,\n\n* Pregnant women under 14 weeks gestation,\n* Singleton gestation,\n* Body mass index \\> 30 kg\u002Fm2\n* Willing to participate in ENHANCE CVH for 2 years,\n* Planning to receive prenatal care and deliver at either one of the participating primary healthcare, centers or University of Abuja Teaching Hospital, and\n* Able to give informed consent for study participation, understanding she and her child will both be involved.\n\nExclusion Criteria:\n\n* Current enrollment in a weight loss program,\n* Inability to engage in a walking program,\n* Active substance abuse\n* Treatment with medications known to impact weight (e.g., corticosteroids, antipsychotics),\n* Plan to relocate within the next 2 years, or\n* Unwilling to provide informed consent.",{"count":227,"type":22},1000,[25],"The purpose of the ENHANCE-CVH study is to promote intergenerational cardiovascular health (CVH) of women and children in Abuja and the surrounding Federal Capital Territory of Nigeria. The study team plans to achieve this through an adaptation of an existing evidence based intervention - Parents as Teachers (PAT) curriculum + Healthy Eating Active Living Taught at Home (HEALTH) - among pregnant women with obesity and their children in Nigeria. The aim of the study is to evaluate the effectiveness and implementation of community health educator-led delivery of the PAT+HEALTH intervention via home visits to answer the following main questions:\n\n* Will the women participating in the intervention have a greater change in weight from baseline to 18-month follow up compared to the women who do not?\n* Will the women and children in the intervention group display better CVH promoting lifestyle behaviors compared to those in the control group?\n\nParticipants in the study will complete baseline surveys and have clinical data, lab data, and body measurements captured. Participants will also have these procedures repeated at birth and every 6 months up to 24 months post-delivery. Once randomized to the intervention group, participants will complete 40 biweekly PAT+HEALTH curriculum delivery sessions, each lasting approximately 60-90 minutes.",[28,36,231,232,233],"Obesity and Overweight","Maternal Morbidity and Mortality","Maternal and Child Health Outcomes",[235,236,237,238],"Maternal Hypertension","Maternal and infant cardiovascular health","Hybrid Type 2 effectiveness-implementation","Obesity in pregnancy","2025-06-24",{"date":241,"type":45},"2025-06-27",{"date":243,"type":45},"2025-06-23",{"date":187,"type":22},{"name":246,"class":52},"Washington University School of Medicine",{"id":248,"slug":249,"hasResults":11,"nctId":250,"briefTitle":251,"officialTitle":252,"acronym":253,"eligibilityCriteria":254,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":255,"enrollmentInfo":256,"targetDuration":4,"studyType":23,"phases":258,"briefSummary":259,"conditions":260,"keywords":263,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":270,"lastUpdatePostDateStruct":271,"startDateStruct":273,"completionDateStruct":275,"leadSponsor":277,"locationsCount":279},"100580866","rhode-island---statewide-postpartum-hypertension-remote-surveillance-100580866","NCT06842875","Rhode Island - Statewide Postpartum Hypertension Remote Surveillance","Effect of a Technology-based Collaborative Model on Persistent Hypertension and Preventive Care Attendance Among Postpartum People With Hypertensive Disorders of Pregnancy","RI-SPHERES","Inclusion Criteria:\n\n* Postpartum patient aged 18 years or more at any birthing hospital in Rhode Island\n* Diagnosed during pregnancy or after delivery with hypertensive disorder of pregnant\n* English-, Spanish-, Portuguese-, or Haitian-Creole-speaking\n* Smartphone ownership\n\nExclusion Criteria:\n\n* Prior enrollment in this trial\n* Prisoners or incarcerated people\n* Inability or unwillingness to provide informed consent\n* Inability to communicate with study team, despite an interpreter","60 Years",{"count":257,"type":22},1536,[25],"This is a hybrid type 1 non-inferiority implementation effectiveness trial among postpartum patients with hypertension (N=1536) that will test the hypothesis that RI-SPHERES (a technologically enabled collaborative care model) is non-inferior to a standard self-measured blood pressure program in terms of persistent hypertension at six weeks postpartum and preventive care receipt within one year of delivery.",[28,261,262],"Postpartum Preeclampsia","Postpartum Complication",[264,265,266,267,268,269],"postpartum hypertensive disorders of pregnancy","postpartum preeclampsia","digital health","collaborative care model","population health","self-measured blood pressure","2025-06-12",{"date":272,"type":45},"2025-06-17",{"date":274,"type":45},"2025-04-15",{"date":276,"type":22},"2029-03-01",{"name":278,"class":52},"Women and Infants Hospital of Rhode Island",5,{"id":281,"slug":282,"hasResults":11,"nctId":283,"briefTitle":284,"officialTitle":285,"acronym":4,"eligibilityCriteria":286,"healthyVolunteers":11,"sex":17,"minAge":287,"maxAge":288,"enrollmentInfo":289,"targetDuration":4,"studyType":23,"phases":291,"briefSummary":292,"conditions":293,"keywords":4,"overallStatus":294,"whyStopped":4,"lastUpdateSubmitDate":295,"lastUpdatePostDateStruct":296,"startDateStruct":297,"completionDateStruct":299,"leadSponsor":301,"locationsCount":53},"100490977","the-outcomes-of-hypertension-in-obese-versus-non-obese-pregnant-women-100490977","NCT05673135","The Outcomes of Hypertension in Obese Versus Non-obese Pregnant Women","The Differences in Adverse Maternal and Fetal Outcomes Related to Hypertension in Obese Versus Non-obese Pregnant Women","Inclusion Criteria:\n\n1. Women aged from 20-35 years.\n2. Pregnant women from 28-30 weeks.\n3. Pregnant women with a singleton pregnancy.\n4. Women with chronic or gestational hypertension.\n5. Women with normal baseline investigations (uncomplicated hypertension).\n6. Obese women and non-obese women.\n\nExclusion Criteria:\n\n1. Women with preeclampsia\u002Feclampsia.\n2. Women need urgent termination of pregnancy.\n3. Women with co-morbidities such as diabetes, renal diseases, cardiac ...etc.\n4. Women with confirmed fetal malformation.\n5. Women who will refuse to participate.","25 Years","35 Years",{"count":290,"type":22},260,[25],"Hypertensive disorders of pregnancy, include pre-existing and gestational hypertension, preeclampsia, and eclampsia, it complicates up to 10% of pregnancies and represents a significant cause of maternal and perinatal morbidity and mortality. Following the \"National High Blood Pressure Education Program Working Group on High Blood Pressure in Pregnancy\" recommendation is currently a systolic blood pressure (SBP) ⩾ of 140 mmHg and diastolic blood pressure (DBP) ⩾ of 90 mmHg. The diagnosis generally requires two separate measurements. Accepted across international guidelines are the following four categories: Chronic\u002Fpre-existing hypertension (Hypertension discovered preconception or prior to 20 weeks gestation), Gestational hypertension (Hypertension that appears de novo after 20 weeks gestation and normalizes after pregnancy), Preeclampsia-eclampsia (De novo hypertension after 20 weeks' gestation accompanied by proteinuria, other features of maternal organ dysfunction or uteroplacental dysfunction), Chronic\u002Fpre-existing hypertension with superimposed preeclampsia-eclampsia. Over the past 2 decades, extensive epidemiologic studies have clearly established that obesity is a major risk for gestational hypertension and preeclampsia. The risk of preeclampsia typically doubles with each 5-7 kg\u002Fm2 increase in pre-pregnancy. The mechanisms have only been partially explored; increased cytokine-mediated inflammation and oxidative stress, increased shear stress, dyslipidemia, and increased sympathetic activity1 have all been proposed as possible pathways. Few studies have examined the relationship between pre-pregnancy BMI, gestational weight gain (GWG), and the risk of preeclampsia. So, our study aims to evaluate the adverse maternal and fetal outcomes related to hypertension in obese and non-obese pregnant women.",[28],"NOT_YET_RECRUITING","2024-04-23",{"date":153,"type":45},{"date":298,"type":22},"2025-04-01",{"date":300,"type":22},"2026-10",{"name":302,"class":52},"Assiut University",{"id":304,"slug":305,"hasResults":11,"nctId":306,"briefTitle":307,"officialTitle":307,"acronym":4,"eligibilityCriteria":308,"healthyVolunteers":11,"sex":17,"minAge":198,"maxAge":4,"enrollmentInfo":309,"targetDuration":4,"studyType":23,"phases":311,"briefSummary":312,"conditions":313,"keywords":314,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":317,"lastUpdatePostDateStruct":318,"startDateStruct":320,"completionDateStruct":322,"leadSponsor":324,"locationsCount":53},"100463036","phase-4-labetalol-or-nifedipine-for-control-of-postpartum-hypertension-a-randomized-controlled-trial-100463036","NCT05309460","Labetalol or Nifedipine for Control of Postpartum Hypertension: A Randomized Controlled Trial","Inclusion Criteria:\n\nAny patient admitted for delivery by cesarean or vaginal delivery at 24 weeks gestation or greater with hypertension(HTN). Hypertension will be defined during the study as either a systolic blood pressure ≥140mmHg or diastolic blood pressure ≥90mmHg on two occasions at least 4 hours apart. This definition is consistent with the ACOG definition for pregnancy related HTN. Following enrollment, treatment will be escalated at discretion of primary provider with the goal of normotension.\n\nExclusion Criteria:\n\nHistory of moderate persistent asthma, coronary artery disease, heart failure, AV heart block, pulmonary edema\n\n* Contraindication to either Nifedipine or Labetalol\n* HR \\\u003C60 or \\>110\n* Native language other than English or Spanish",{"count":310,"type":22},600,[169],"Randomized trial comparing risk of hospital readmission and hypertensive complications between patients managed on Labetalol compared to Nifedipine.",[261,28],[207,315,205,36,316,70],"Labetalol","Preeclampsia","2024-04-10",{"date":319,"type":45},"2024-04-12",{"date":321,"type":45},"2022-06-20",{"date":323,"type":22},"2024-12-01",{"name":217,"class":52},{"id":326,"slug":327,"hasResults":11,"nctId":328,"briefTitle":329,"officialTitle":330,"acronym":331,"eligibilityCriteria":332,"healthyVolunteers":11,"sex":333,"minAge":334,"maxAge":335,"enrollmentInfo":336,"targetDuration":4,"studyType":337,"phases":4,"briefSummary":338,"conditions":339,"keywords":344,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":348,"lastUpdatePostDateStruct":349,"startDateStruct":351,"completionDateStruct":353,"leadSponsor":355,"locationsCount":53},"100491743","cardiovascular-longitudinal-alspac-research-investigations-following-hypertensive-pregnancy-in-young-adulthood-100491743","NCT05683093","Cardiovascular Longitudinal ALSPAC Research Investigations Following Hypertensive Pregnancy in Young Adulthood","Cardiovascular Longitudinal the Avon Longitudinal Study of Parents and Children (ALSPAC) Research Investigations Following Hypertensive Pregnancy in Young Adulthood","CLARITY","Inclusion Criteria:\n\n* Participant is willing and able to give informed consent for participation in the study\n* Male or female, aged 30 to 40 years at time of enrolment\n* Participant previously took part in the ALSPAC study\n* Able (in the investigator's opinion) and willing to comply with all study requirements\n* Adequate understanding of verbal and written English\n\nExclusion Criteria:\n\n* Pregnant or lactating when they are due to attend for study visit 1\n* Less than six months postpartum\n* Planning to donate blood within two weeks prior to study visit 1\n* Any significant disease or disorder which, in the opinion of the investigator, might influence the participant's ability to participate in the study\n* Evidence of congenital heart disease or significant chronic disease relevant to cardiovascular or metabolic status\n\nFor exclusion of MRI component only:\n\n* Unsuitable for MRI based on participant screening; the participant may still be included in other parts of the study","ALL","30 Years","40 Years",{"count":167,"type":22},"OBSERVATIONAL","The purpose of this study is to understand more about why young people who were born to a hypertensive pregnancy may have increased risk of high blood pressure and are often at increased risk of heart and blood vessel disease later in life.",[340,28,36,341,342,343],"Young Adult","Cardiovascular Diseases","Cerebrovascular Diseases","Vascular Diseases",[340,345,28,346,347],"Birth History","Cardiovascular Risk","Exercise Capacity","2023-01-05",{"date":350,"type":45},"2023-01-12",{"date":352,"type":45},"2022-11-17",{"date":354,"type":22},"2027-01-31",{"name":356,"class":52},"University of Oxford"]